metricas
covid
Buscar en
Enfermedades Infecciosas y Microbiología Clínica
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica Antimicrobial and immunosuppressive drug interactions in solid organ transplant ...
Información de la revista
Vol. 30. Núm. S2.
Infections in solid organ transplantation
Páginas 86-92 (marzo 2012)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 30. Núm. S2.
Infections in solid organ transplantation
Páginas 86-92 (marzo 2012)
Acceso a texto completo
Antimicrobial and immunosuppressive drug interactions in solid organ transplant recipients
Interacciones entre antimicrobianos y fármacos inmunosupresores en receptores de trasplante de órgano sólido
Visitas
3106
Soledad Berdaguera, Javier Bautistab, Mercè Brunetc, José Miguel Cisnerosd,
Autor para correspondencia
jmcisnerosh@gmail.com

Corresponding author.
a Department of Pharmacology, Hospital Universitario Virgen del Rocío-IBIS, Seville, Spain
b Clinical Pharmacy Unit, Hospital Universitario Virgen del Rocío-IBIS, Seville, Spain
c Department of Pharmacology, Hospital Clínic-IDIBAPS, Barcelona, Spain
d Infectious Diseases, Microbiology and Preventive Medicine Unit, Hospital Universitario Virgen del Rocío-IBIS, Seville, Spain
Este artículo ha recibido
Información del artículo
Abstract

Infections are frequent and can be severe in recipients of solid organ transplantation. Prevention and treatment are priority objectives of multidisciplinary transplant teams. Interactions between antimicrobials (indicated for prevention and therapy) and immunosuppressants (for preventing rejection) make treatment more complex than in the general population. Co-administration of immunosuppressants and antibiotics can cause harmful interactions, modifying the pharmacokinetic and pharmacodynamic characteristics of both groups of drugs. The loss of the transplanted organ due to reduced levels of immunosuppressants is a unique consequence of the often lethal interactions in this group of patients. By contrast, elevated levels of these drugs cause toxicity, and reduced concentrations of antimicrobial treatment fail to contain the infection. Azoles, rifabutin, protease inhibitors, non-nucleoside reverse transcriptase inhibitors and antimicrobial macrolides all interact with immunosuppressants. In this article, we review interactions between antibiotics and immunosuppressants in order to adopt the most appropriate clinical approach (dosage adjustments, close monitoring of plasma levels and organ function) and determine whether they can be used together with any measure of safety.

Keywords:
Antibacterials
Antifungals
Antimicrobials
Antiretrovirals
Antivirals
Drug interaction
Immunosuppressants
Transplantation
Resumen

Las infecciones son frecuentes y más graves en receptores de trasplante de órgano sólido. La prevención y tratamiento es una prioridad objetiva de los equipos multidisciplinarios de trasplante. Las interacciones entre el antimicrobiano indicado para prevención y tratamiento y los inmunosupresores para prevenir el rechazo, hacen más complejo al tratamiento que en la población general. La coadministración de inmunosupresores y antibióticos puede causar interacciones perjudiciales, modificando las características farmacocinéticas y farmacodinámicas de ambos grupos de fármacos. La pérdida del órgano trasplantado por los niveles reducidos del inmunosupresor es una consecuencia excepcional de las interacciones en este grupo de pacientes, a menudo letal. Por el contrario, los niveles elevados de estos fármacos causan toxicidad y las concentraciones reducidas de antimicrobianos, fallo del tratamiento de la infección. Los azoles, la rifabutina, los inhibidores de la proteasa, los inhibidores no nucleósidos de la transcriptasa reversa y los antibióticos macrólidos son los fármacos que presentan más interacciones con los inmunosupresores. En este capítulo revisamos las interacciones entre los antibióticos y los inmunosupresores para, en consecuencia, adoptar la decisión clínica más conveniente: ajustar las dosis de los fármacos, realizar un control exhaustivo de los niveles plasmáticos o del funcionamiento del órgano o, por el contrario, si pueden ser utilizados con seguridad.

Palabras clave:
Antibacterianos
Antimicrobianos
Antifúngicos
Antivirales
Inmunosupresores
Interacción farmacológica
Trasplante
El Texto completo está disponible en PDF
References
[1.]
A. Termeer, A.J. Hoitsma, R.A. Koene.
Severe nephrotoxicity caused by the combined use of gentamicin and ciclosporine in renal allograft recipients.
Transplantation, 42 (1986), pp. 220-221
[2.]
J.M. Hows, P.M. Chipping, S. Fairhead, J. Smith, A. Baughan, E.C. Gordon-Smith.
Nephrotoxicity in bone marrow transplant recipients treated with ciclosporine A.
Br J Haematol, 54 (1983), pp. 69-78
[3.]
Novartis Spain. Sanndimmun neoral (ciclosporin microemulsion). Spanish summary of product characteristics. June 2011.
[4.]
F. Jahansouz, J.M. Kriett, C.M. Smith, S.W. Jamieson.
Potentiation of ciclosporin nephrotoxicity by nafcillin in lung transplant recipients.
Transplantation, 55 (1993), pp. 1045-1048
[5.]
R. Borrows, G. Chusney, M. Loucaidou, A. James, J. Van Tromp, T. Cairns, et al.
The magnitude and time course of changes in mycophenolic acid 12-hour predose levels during antibiotic therapy in mycophenolate mofetil based renal transplantation.
Ther Drug Monit, 29 (2007), pp. 122-126
[6.]
B. Sádaba, A. López de Ocáriz, J.R. Azanza, J. Quiroga, J.A. Cienfuegos.
Concurrent clarithromycin and ciclosporin A treatment.
J Antimicrob Chemother, 42 (1998), pp. 393-395
[7.]
J.D. Harnett, P.S. Parfrey, M.D. Paul, M.H. Gault.
Erythromycin-ciclosporine interaction in renal transplant patients.
Transplantation, 43 (1987), pp. 316-318
[8.]
P.W. Kunicki, M. Sobieszczanska-Malek.
Pharmacokinetic interaction between tacrolimus and clarithromycin in a heart transplant patient.
Ther Drug Monit, 27 (2005), pp. 107-108
[9.]
C. Jensen, M. Jordan, R. Shapiro, V. Scantlebury, T. Hakala, J. Fung, et al.
Interaction between tacrolimus and erythromycin.
Lancet, 344 (1994), pp. 825
[10.]
D. Capone, G. Palmiero, A. Gentile, V. Basile, S. Federico, M. Sabbatini, et al.
A pharmacokinetic interaction between clarithromycin and sirolimus in kidney transplant recipient.
Curr Drug Metab, 8 (2007), pp. 379-381
[11.]
K. Claesson, C. Brattström, J.T. Burke.
Sirolimus and erythromycin interaction: two cases.
Transplant Proc, 33 (2001), pp. 2136
[13.]
J.M. Kovarik, D. Beyer, M.N. Bizot, Q. Jiang, M. Shenouda, R.L. Schmouder.
Effect of multiple-dose erythromycin on everolimus pharmacokinetics.
Eur J Clin Pharmacol, 61 (2005), pp. 35-38
[14.]
D.A. Fost, D.Y. Leung, R.J. Martin, E.E. Brown, S.J. Szefler, J.D. Spahn.
Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy.
J Allergy Clin Immunol, 103 (1999), pp. 1031-1035
[15.]
C.F. LaForce, S.J. Szefler, M.F. Miller, W. Ebling, M. Brenner.
Inhibition of methylprednisolone elimination in the presence of erythromycin therapy.
J Allergy Clin Immunol, 72 (1983), pp. 34-39
[16.]
S.J. Szefler, J.Q. Rose, E.F. Ellis, S.L. Spector, A.W. Green, W.J. Jusko.
The effect of troleandomycin on methylprednisolone elimination.
J Allergy Clin Immunol, 66 (1980), pp. 447-451
[17.]
O.J. Naderer, R.E. Dupuis, E.L. Heinzen, K. Wiwattanawongsa, M.W. Johnson, P.C. Smith.
The influence of norfloxacin and metronidazole on the disposition of mycophenolate mofetil.
J Clin Pharmacol, 45 (2005), pp. 219-226
[18.]
A.E. El-Agroudy, A.F. Refaie, O.M. Moussa, M.A. Ghoneim.
Tuberculosis in Egyptian kidney transplant recipients: study of clinical course and outcome.
J Nephrol, 16 (2003), pp. 404-411
[19.]
M.F. Hebert, R.M. Fisher, C.L. Marsh, D. Dressler, I. Bekersky.
Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers.
J Clin Pharmacol, 39 (1999), pp. 91-96
[20.]
M. Naesens, D.R. Kuypers, F. Streit, V.W. Armstrong, M. Oellerich, K. Verbeke, et al.
Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients.
Clin Pharmacol Ther, 80 (2006), pp. 509-521
[21.]
J.M. Kovarik, S. Hartmann, J. Figueiredo, M. Rouilly, A. Port, C. Rordorf.
Effect of rifampicin on apparent clearance of everolimus.
Ann Pharmacother, 36 (2002), pp. 981-985
[23.]
V. Kyriazopoulou, O. Parparousi, A.G. Vagenakis.
Rifampicin-induced adrenal crisis in addisonian patients receiving corticosteroid replacement therapy.
J Clin Endocrinol Metab, 59 (1984), pp. 1204-1206
[24.]
W.A. McAllister, P.J. Thompson, S.M. Al-Habet, H.J. Rogers.
Rifampicin reduces effectiveness and bioavailability of prednisolone.
Br Med J (Clin Res Ed), 286 (1983), pp. 923-925
[25.]
Monarch Pharmaceuticals Ireland Ltd. Synercid (Quinupristin/Dalfopristin). UK Summary of product characteristics, March 2005.
[26.]
I. Raad, R. Hachem, H. Hanna.
Relationship between myalgias/arthralgias occurring in patients receiving quinupristin/dalfopristin and biliary dysfunction.
J Antimicrob Chemother, 53 (2004), pp. 1105-1108
[27.]
E. Dodds-Ashley.
Management of drug and food interactions with azole antifungal agents in transplant recipients.
Pharmacotherapy, 30 (2010), pp. 842-854
[28.]
A.H. Saad, D.D. DePestel, P.L. Carver.
Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants.
Pharmacotherapy, 26 (2006), pp. 1730-1744
[31.]
G. Eschenauer, D.D. DePestel, P.L. Carver.
Comparison of echinocandin antifungals.
Ther Clin Risk Manag, 3 (2007), pp. 71-97
[32.]
T. Kuramoto, T. Daikoku, Y. Yoshida, M. Takemoto, K. Oshima, Y. Eizuru, et al.
Novel anticytomegalovirus activity of immunosuppressant mizoribine and its synergism with ganciclovir.
J Pharmacol Exp Ther, 333 (2010), pp. 816-821
[33.]
W.C. Su, W.L. Liu, C.W. Cheng, Y.B. Chou, K.H. Hung, W.H. Huang, et al.
Ribavirin enhances interferon signaling via stimulation of mTOR and p53 activities.
FEBS Lett, 583 (2009), pp. 2793-2798
Copyright © 2012. Elsevier España S.L.. All rights reserved
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos